The emerging role of fumarate as an oncometabolite

Ming Yang, Tomoyoshi Soga, Patrick J. Pollard, Julie Adam

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

The drive to understand how altered cellular metabolism and cancer are linked has caused a paradigm shift in the focus of cancer research. The discovery of a mutated metabolic enzyme, isocitrate dehydrogenase 1, that leads to accumulation of the oncometabolite 2-hydroxyglutarate, provided significant direct evidence that dysfunctional metabolism plays an important role in oncogenesis. Striking parallels exist with the Krebs cycle enzyme fumarate hydratase (FH), a tumor suppressor, whose mutation is associated with the development of leiomyomata, renal cysts, and tumors. Loss of FH enzymatic activity results in accumulation of intracellular fumarate which has been proposed to act as a competitive inhibitor of 2-oxoglutarate-dependent oxygenases including the hypoxia-inducible factor (HIF) hydroxylases, thus activating oncogenic HIF pathways. Interestingly, our studies have questioned the role of HIF and have highlighted other candidate mechanisms, in particular the non-enzymatic modification of cysteine residues (succination) that could lead to disruption or loss of protein functions, dysfunctional cell metabolism and cell signaling. Here, we discuss the evidence for proposing fumarate as an onco-metabolite.

Original languageEnglish
Article numberArticle 85
JournalFrontiers in Oncology
Volume2 JUL
DOIs
Publication statusPublished - 2012

Fingerprint

Fumarates
Fumarate Hydratase
Neoplasms
Genetic Suppression
Isocitrate Dehydrogenase
Oxygenases
Citric Acid Cycle
Leiomyoma
Enzymes
Mixed Function Oxygenases
Cysteine
Cysts
Carcinogenesis
Kidney
Research
Hypoxia
Proteins

Keywords

  • Dysregulated metabolism
  • Fumarate
  • Mitochondrial dysfunction
  • Oncometabolite
  • Succination

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The emerging role of fumarate as an oncometabolite. / Yang, Ming; Soga, Tomoyoshi; Pollard, Patrick J.; Adam, Julie.

In: Frontiers in Oncology, Vol. 2 JUL, Article 85, 2012.

Research output: Contribution to journalArticle

Yang, Ming ; Soga, Tomoyoshi ; Pollard, Patrick J. ; Adam, Julie. / The emerging role of fumarate as an oncometabolite. In: Frontiers in Oncology. 2012 ; Vol. 2 JUL.
@article{fc714ee3f2f94a0ea777a5a60514789c,
title = "The emerging role of fumarate as an oncometabolite",
abstract = "The drive to understand how altered cellular metabolism and cancer are linked has caused a paradigm shift in the focus of cancer research. The discovery of a mutated metabolic enzyme, isocitrate dehydrogenase 1, that leads to accumulation of the oncometabolite 2-hydroxyglutarate, provided significant direct evidence that dysfunctional metabolism plays an important role in oncogenesis. Striking parallels exist with the Krebs cycle enzyme fumarate hydratase (FH), a tumor suppressor, whose mutation is associated with the development of leiomyomata, renal cysts, and tumors. Loss of FH enzymatic activity results in accumulation of intracellular fumarate which has been proposed to act as a competitive inhibitor of 2-oxoglutarate-dependent oxygenases including the hypoxia-inducible factor (HIF) hydroxylases, thus activating oncogenic HIF pathways. Interestingly, our studies have questioned the role of HIF and have highlighted other candidate mechanisms, in particular the non-enzymatic modification of cysteine residues (succination) that could lead to disruption or loss of protein functions, dysfunctional cell metabolism and cell signaling. Here, we discuss the evidence for proposing fumarate as an onco-metabolite.",
keywords = "Dysregulated metabolism, Fumarate, Mitochondrial dysfunction, Oncometabolite, Succination",
author = "Ming Yang and Tomoyoshi Soga and Pollard, {Patrick J.} and Julie Adam",
year = "2012",
doi = "10.3389/fonc.2012.00085",
language = "English",
volume = "2 JUL",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - The emerging role of fumarate as an oncometabolite

AU - Yang, Ming

AU - Soga, Tomoyoshi

AU - Pollard, Patrick J.

AU - Adam, Julie

PY - 2012

Y1 - 2012

N2 - The drive to understand how altered cellular metabolism and cancer are linked has caused a paradigm shift in the focus of cancer research. The discovery of a mutated metabolic enzyme, isocitrate dehydrogenase 1, that leads to accumulation of the oncometabolite 2-hydroxyglutarate, provided significant direct evidence that dysfunctional metabolism plays an important role in oncogenesis. Striking parallels exist with the Krebs cycle enzyme fumarate hydratase (FH), a tumor suppressor, whose mutation is associated with the development of leiomyomata, renal cysts, and tumors. Loss of FH enzymatic activity results in accumulation of intracellular fumarate which has been proposed to act as a competitive inhibitor of 2-oxoglutarate-dependent oxygenases including the hypoxia-inducible factor (HIF) hydroxylases, thus activating oncogenic HIF pathways. Interestingly, our studies have questioned the role of HIF and have highlighted other candidate mechanisms, in particular the non-enzymatic modification of cysteine residues (succination) that could lead to disruption or loss of protein functions, dysfunctional cell metabolism and cell signaling. Here, we discuss the evidence for proposing fumarate as an onco-metabolite.

AB - The drive to understand how altered cellular metabolism and cancer are linked has caused a paradigm shift in the focus of cancer research. The discovery of a mutated metabolic enzyme, isocitrate dehydrogenase 1, that leads to accumulation of the oncometabolite 2-hydroxyglutarate, provided significant direct evidence that dysfunctional metabolism plays an important role in oncogenesis. Striking parallels exist with the Krebs cycle enzyme fumarate hydratase (FH), a tumor suppressor, whose mutation is associated with the development of leiomyomata, renal cysts, and tumors. Loss of FH enzymatic activity results in accumulation of intracellular fumarate which has been proposed to act as a competitive inhibitor of 2-oxoglutarate-dependent oxygenases including the hypoxia-inducible factor (HIF) hydroxylases, thus activating oncogenic HIF pathways. Interestingly, our studies have questioned the role of HIF and have highlighted other candidate mechanisms, in particular the non-enzymatic modification of cysteine residues (succination) that could lead to disruption or loss of protein functions, dysfunctional cell metabolism and cell signaling. Here, we discuss the evidence for proposing fumarate as an onco-metabolite.

KW - Dysregulated metabolism

KW - Fumarate

KW - Mitochondrial dysfunction

KW - Oncometabolite

KW - Succination

UR - http://www.scopus.com/inward/record.url?scp=84875804944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875804944&partnerID=8YFLogxK

U2 - 10.3389/fonc.2012.00085

DO - 10.3389/fonc.2012.00085

M3 - Article

AN - SCOPUS:84875804944

VL - 2 JUL

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 85

ER -